Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Deferred Tax Liability (2021 - 2024)

Prime Medicine filings provide 4 years of Non-Current Deferred Tax Liability readings, the most recent being $134000.0 for Q1 2024.

  • On a quarterly basis, Non-Current Deferred Tax Liability rose 74.03% to $134000.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $134000.0, a 74.03% increase, with the full-year FY2022 number at $8.7 million, up 46.57% from a year prior.
  • Non-Current Deferred Tax Liability hit $134000.0 in Q1 2024 for Prime Medicine, up from $108000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $8.7 million in Q4 2022 to a low of $77000.0 in Q1 2023.
  • Median Non-Current Deferred Tax Liability over the past 4 years was $307500.0 (2022), compared with a mean of $2.6 million.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: surged 46.57% in 2022 and later skyrocketed 74.03% in 2024.
  • Prime Medicine's Non-Current Deferred Tax Liability stood at $6.0 million in 2021, then skyrocketed by 46.57% to $8.7 million in 2022, then plummeted by 98.77% to $108000.0 in 2023, then rose by 24.07% to $134000.0 in 2024.
  • The last three reported values for Non-Current Deferred Tax Liability were $134000.0 (Q1 2024), $108000.0 (Q2 2023), and $77000.0 (Q1 2023) per Business Quant data.